Type 2 Diabetes

The US FDA has granted clearance to the FreeStyle Libre 2 and FreeStyle Libre 3 sensors for integration with automated insulin delivery systems. Abbott, which noted ongoing collaborations with Insulet and Tandem, expects the modified sensors to be available in the US later this year.

A recap of the top news and research from the 16th annual meeting for Advanced Technologies and Treatments for Diabetes in Berlin, Germany.

After Eli Lilly and Company announced major reductions in list prices for multiple insulin products, the community rejoiced at the though of taking a major step forward toward equitable access to insulin. Learn more about the reaction from major organizations and those within the field.

In this episode, Stuart Weinzimer, MD sits down with hosts for a discussion on his research and experience with diabetes technology, the need to focus on patient-reported outcomes in pediatric diabetes, and strategies for meeting the practical needs of individuals with diabetes.

A trio of studies presented at ATTD 2023 detail the strengths and limitations of real-time continuous glucose monitoring technologies in an array of patient populations and settings.

In this episode, hosts are joined by Grazia Aleppo, MD, to discuss the development of guideline recommendations for diabetes technology as well as her top takeaways from the ATTD 2023 meeting.

Data from a trio of studies presented at ATTD 2023 provide insight into the utility of the Omnipod 5 across multiple patient populations as well as use for use in inpatient settings.

Announced on March 1, Eli Lilly and Company's reduction in insulin product list prices includes non-branded insulin lispro, Rezvoglar, KwikPens, Humulin, and Humalog. The company would also be instituting an out-of-pocket cost cap of $35 for most insulin users.

Hosts are joined by the associate director of Medical Affairs and Medical Education at MannKind for a special edition episode from ATTD 23 that focuses on use of inhaled insulin and future research plans for MannKind.

In this episode, hosts are joined by Marissa Town, BSN, RN, and Renza Scibilia for a discussion centered around the role of the patient voice in diabetes management while on site at ATTD 2023.

Medha Munshi, MD, discusses the concept of healthy aging in diabetes and offers perspective on contemporary trends in hurdles and optimized strategies to achieve healthy aging in people with diabetes.

In this episode, Irl Hirsch, MD, discusses a study he is conducting examining skin changes associated with insulin pump use in people with type 1 diabetes. Later in the episode, Hirsch discusses what he is most excited about in terms of ongoing and future research in diabetes management.

In this episode from ATTD 2023, hosts are joined by Joanne Rinker, MS, RDN, who provides perspective on hearing loss in diabetes, including prevalence, the need for screening, and the underecognition of auditory issues in the midst of a growing population of people with diabetes.

In this episode, hosts sit down with Katharine Barnard-Kelly, PhD, at ATTD 2023 to discuss the evolving recognition of the role of psychology in diabetes management for both pediatric and adult populations.

A study and a subanalysis of the same study presented at ATTD 23 demonstrate use of the FreeStyle Libre flash glucose monitoring system was associated with improved treatment satisfaction and HbA1c.

At ATTD 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, have an extended conversation with the new chief operating officer at Dexcom, Jake Leach, to discuss the global and US rollouts of the Dexcom G7 and what the future might hold for Dexcom.

David Maahs, MD, PhD, sits down to discuss data he presented at ATTD 2023 and provide perspective on ongoing issues plaguing the diabetes community, including optimization of telehealth and addressing disparities in care.

An analysis of Veterans Affairs data from more than 20,000 people with diabetes provides an overview of the associations of CGM initiation with improved glycemic control and reduced hospitalization in this patient population.

Using data from a pair of major studies, investigators from the Harvard T.H. Chan School of Public Health shed new light on the impact of low-carbohydrate diet scores in people with type 2 diabetes.

An analysis of data from more than 20,000 adults with a documented COVID-19 infection from Los Angeles, CA has brought forth results the investigators suggest prove the association between COVID-19 infection and increased risk of type 2 diabetes, regardless of vaccination status.

An analysis of the HAPO Follow-up Study is shedding light on associations between birth weight categories and risk of diabetes 10-14 years after delivery in mothers.

Drs Diana Isaacs and Natalie Bellini highlight the need for engaging patients in shared decision-making and addressing social determinants of health in diabetes and obesity management in adults and pediatric patients.

Scott Kahan, MD, MPH, discusses with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, how the controversial use of new diabetes and obesity medications is creating access issues for people who really need these medications, and shares strategies to initiate the conversation about weight management with patients.

Dr Scott Kahan shares the latest updates to the 2023 ADA Standards of Care related to weight management and describes the different weight loss approaches recommended by the ADA.

Scott Kahan, MD, MPH, discusses the shortcomings of the current staging systems used for overweight and obesity and recommends the use of weight-related health and functional status in addition to BMI.

Further adding to the discussion surrounding the impact of endocrine-disrupting chemicals, an analysis of data from the SWAN Multipollutant Study suggests increased exposure to phthlates was linked to a 30-63% increase in risk of developing diabetes among White women in midlife.

Leveraging data from the Tromsø study, the D2d study, and the DPVD study, a systematic review and meta-analysis concluded vitamin D supplementation could help reduce risk of progression to diabetes by 15% among people with prediabetes.

A new-user comparator study of adults with type 2 diabetes indicates use of SGLT2 inhibitors was associated with a 54% lower risk of hospitalizations for heart failure and a 15% lower risk of a modified MACE outcome compared to use of DPP-4 inhibitors.

Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.

The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.